title: Immunostimulatory effects of polar glycopeptidolipids of Mycobacterium chelonae for inactivated rabies vaccine.
abstract: Humoral and cellular immune responses were analyzed with Fuenzalida-Palacios rabies vaccine associated with pGPL-Mc, polar glycopeptidolipids extracted from Mycobacterium chelonae, aiming at its use as adjuvant. These results were compared to those obtained with BCG, a well-known immunostimulator, under the same conditions. Rabies vaccine plus pGPL-Mc (2.5 mg/kg) induced a significant increase in serum neutralizing activity, in vitro lymphocyte proliferation (spontaneous, specific and mitogen stimulation) and delayed type hypersensibility. In addition, pGPL-Mc, as well as BCG, enhanced the vaccine potency. Our results support further studies to encourage the use of pGPL-Mc as an immunostimulator of veterinary vaccines, before consideration for human vaccines.
authors.affiliation: Instituto Oswaldo Cruz, Rio de Janeiro, Brazil.
authors.forename: D C
authors.initials: DC
authors.lastname: de Souza Matos
authors.forename: R
authors.initials: R
authors.lastname: Marcovistz
authors.forename: T
authors.initials: T
authors.lastname: Neway
authors.forename: A M
authors.initials: AM
authors.lastname: Vieira da Silva
authors.forename: E N
authors.initials: EN
authors.lastname: Alves
authors.forename: C
authors.initials: C
authors.lastname: Pilet
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000276:immunology; D000942:Antigens, Bacterial / Q000009:adverse effects / Q000276:immunology*; D001500:BCG Vaccine / Q000276:immunology; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D005260:Female; D006020:Glycopeptides / Q000009:adverse effects / Q000276:immunology*; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000209:etiology; D007111:Immunity, Cellular; D007372:Interferons / Q000096:biosynthesis; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D016926:Mycobacterium chelonae / Q000276:immunology*; D009500:Neutralization Tests; D011819:Rabies Vaccines / Q000009:adverse effects / Q000276:immunology*; D011820:Rabies virus / Q000276:immunology*; D012449:Safety; D013154:Spleen / Q000276:immunology; D013950:Thymus Gland / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D000942:Antigens, Bacterial; D001500:BCG Vaccine; D006020:Glycopeptides; D011819:Rabies Vaccines; D007372:Interferons